Trial: 201808202

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Phase

III

Principal Investigator

Vij, Ravi

Disease Site

Multiple Myeloma

Learn more about this study at: clinicaltrials.gov